On Wednesday, October 21, 2015, the Lupus Foundation of America honored several key supporters of the fight against systemic lupus erythematosus (SLE) at the Evening of Hope New York City Gala. The efforts of Alan Siegel, President and Chief Executive Officer, Siegelvision; Fran Tsimoyianis, Executive Assistant, Office of the Chairman, Hudson’s Bay Company;…
The upcoming and highly anticipated Cardiovascular, Renal and Metabolic Diseases: Physiology and Gender conference, set to take place November 17–20 in Annapolis, Maryland, will be hosted by the American Physiology Society — one of the country’s oldest societies in the field of biomedical sciences, with over 11,000 members and 14 peer-reviewed journals…
The University of Rochester Medical Center’s (UR Medicine) Lupus Clinic is preparing for its ninth annual Lupus Education Day, which is running on Saturday, October 31, 2015, at 3:30 p.m. at the Helen Wood Hall, 255 Crittenden Blvd. Local patients, their loved ones, and caregivers are all invited to this free…
XTL Biopharmaceuticals Ltd. and Yeda Research and Development Company Ltd. have strengthened their collaboration to develop a new therapy for systemic lupus erythematosus (SLE), called hCDR1. The two companies recently signed an amended agreement altering the development milestones featured in the License Agreement signed…
Mallinckrodt Pharmaceuticals recently announced that results from a pilot clinical study for its H.P. Acthar Gel will be presented during the 2015 Annual Meeting of the American College of Rheumatology (ACR) that will take place in San Francisco from 7th until the 11th of November. The pilot…
Results from a recent study published in the Journal of Rheumatology revealed that patients with systemic lupus erythematosus (SLE) who have low blood levels of prescribed hydroxychloroquine were more likely to have high disease activity. Hydroxychloroquine (HCQ) is in a class of drugs called antimalarials and is…
The leading organization in the U.S. dedicated to addressing lupus, The Lupus Foundation of America, has just revealed the recipients of five research grants, awarded under the Foundation’s commitment to support lupus-focused researchers in conducting clinical trials necessary to better understanding and eventually curing this life-altering autoimmune disease. “The researchers…
A history of thrombocytopenia is a strong predictor of diffuse alveolar haemorrhage (DAH) in patients with systemic lupus erythematosus, according to the results of a recent study published in the journal Lupus, Science & Medicine. Systemic lupus erythematosus (SLE) is an autoimmune disease in…
Studies have revealed there is a gap between what lupus patients experience and what they tell their clinicians with results from a recent survey showing that closing this gap may lead to better communication and improved clinical management of the disease. The 2014 online survey funded and developed by GSK included 905 global respondents…
The Alliance for Lupus Research (ALR), a national volunteer health organization dedicated to finding better treatments and ultimately preventing and cure systemic lupus erythematosus (SLE, or lupus) has contributed more than $100 million to research and development for SLE. ALR recently sponsored New York Jets guard Willie Colon’s 1st Annual…